Literature DB >> 7416617

A service program of antituberculosis chemotherapy with five drugs for four months in the treatment of drug addicts and prisoners with pulmonary tuberculosis in Hong Kong. Hong Kong Chest Service/British Medical Research Council.

.   

Abstract

The results are reported of a service in Hong Kong of intensive antituberculosis chemotherapy with 5 drugs given daily for 4 months, or until discharge from hospital or release from prison if earlier, in the treatment of male Chinese drug addicts and prisoners who had pulmonary tuberculosis positive for acid-fast bacilli on microscopic examination of the sputum. Of 69 patients who received 4 months of chemotherapy, all those with sputum cultures negative for M. tuberculois initially, and more than 80% of those with positive cultures, 41% of whom had strains resistant to isoniazid, streptomycin, or both drugs, achieved quiescent disease, which was maintained for a year of follow-up. Some of the patients who received less than 4 months of chemotherapy also reponded well. Despite the 5 drugs, the frequency of adverse reactions to the regimen was low.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7416617     DOI: 10.1164/arrd.1980.122.3.417

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  2 in total

Review 1.  Short-course therapy for tuberculosis.

Authors:  M Aquinas
Journal:  Drugs       Date:  1982-08       Impact factor: 9.546

2.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.